The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma
Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, shares insights into a first-in-human Phase I trial investigating the safety and efficacy of combining a gamma secretase inhibitor (GSI) with BCMA CAR-T cells in patients with relapsed/refractory (R/R) multiple myeloma. GSIs are agents which increase BCMA density on plasma cells, and results suggest that combining these two agents may provide a benefit to patients, although further research is required. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar
